Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration

Kamphuis, Bregtje; Kanavos, Panos

doi:10.1016/j.hpopen.2021.100045

Cited by 7 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To enhance generic acceptance, countries should develop, apply, and execute guidelines for utilizing generic medication. 43 Given the region’s inherent distrust of generics, procurement regulations concentrating on costs and compensation could be incapable of achieving performance and cost goals. Such change should be accompanied by identifying the market policies on generic medicines and alternatives and regulatory capacity strengthening if necessary.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review

Mirza¹,

Alqasomi²,

El‐Dahiyat³

et al. 2023

IPRP

View full text Add to dashboard Cite

Introduction This scoping review includes studies on pharmaceutical access, shortages, generics, availability, pharmacoeconomics, and pricing restrictions. The study’s findings may aid in developing excellent pharmaceutical and access policies in the country. Objective To conduct a scoping review documenting access to medicines and Pharmaceutical Policy in Saudi Arabia. Methodology The PRISMA-ScR guidelines were used to perform a scoping review. The articles were screened using databases from Google Scholar, EBSCO, Science Direct, and the University of Huddersfield Library. The selection, aims, results, and conclusion of each original research publication published between 2010 and 2022 were evaluated. To categorize the articles, a theme analysis was done. Results This study includes nineteen publications. The chosen articles revealed four themes. Among these topics were: Access to medications 36.84% Pharmacoeconomic 36.84%), which were the predominant theme followed by Generic Medicines 15.80%, and Cancer drug financing 10.54%. There are myriad challenges related to high-cost medicines. Access restrictions to medications have significant effects on patient morbidity and mortality; as a result, policy decision-makers frequently consider this issue. Access to medicines suffers budgetary limitations and the increasing cost of innovative medicines. Access to medicines for all patients could be significantly impacted by delays in patient access to new therapies. Conclusion The available evidence revealed that Saudi Arabia’s healthcare system has numerous issues ranging from cancer drug financing, medicine shortages, and access issue. In order to achieve the highest health standards possible, it is crucial that each individual has access to medicines and has the financial, physical, and social means to do so. However, the price of some medications can be prohibitive for people who need to obtain them. The study’s outcomes could help the country develop pharmaceutical and access policies related to medicines.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Such change should be accompanied by identifying the market policies on generic medicines and alternatives and regulatory capacity strengthening if necessary. 43 …”

Section: Discussionmentioning

confidence: 99%

Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review

Mirza¹,

Alqasomi²,

El‐Dahiyat³

et al. 2023

IPRP

View full text Add to dashboard Cite

show abstract

“…At issue are questions for medicine developers (and their investors) of the attractiveness of filing in the EU—conditions judged in the light of policies such as regulatory incentives, agile assessment frameworks, data protection, and market exclusivity [ 13 ]. However, for health authorities and payers, as well as many academics and patient representatives, the questions often relate more to judgements of the quality and extent of evidence in support of applications for approval, price, return on public investment, or data privacy [ 14 , 15 ]. HTA and payer bodies frequently complain that supporting data for applications are insufficient for them to reach an informed conclusion on a product’s merits [ 16 ].…”

Section: Discussion: Different Challenges and Opportunitiesmentioning

confidence: 99%

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

et al. 2022

View full text Add to dashboard Cite

Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D) for innovative medicines and treatments is essential for making progress in preventing and treating diseases. Ahead of the legislative process, which should begin by the end of 2022, discussions focus on how Europe can best promote the huge potential benefits of new science and technology within the regulatory framework. The challenges in European healthcare were spelled out by the panellists at the roundtable organised by European Alliance for Personalised Medicine (EAPM). Outcomes from panellists’ discussions have been summarized and re-arranged in this paper under five headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency. Some of the conclusions that emerged from the panel are a call for a better overall holistic vision of the future of pharmaceuticals and health in Europe and a collaborative effort among all stakeholders, seeing the delivery of medicines as part of a broader picture of healthcare.

show abstract

“…In Lebanon, tendering and formulary management are dominant in generic procurement, but in Qatar, reimbursement is achieved through a combination of different measures, involving tendering, formulary management and IRP. Support provided to local manufacturers includes predominantly discriminatory reimbursement practices favoring local over multinational manufacturers (seen in Bahrain, Jordan, Kuwait, Lebanon, Qatar, and Saudi Arabia), and generic pricing policies to encourage local production and provide more beneficial pricing arrangements to local over imported generics [ 109 ]. In Jordan, public sector procurement is performed through annual tenders issued in the generic name of the pharmaceuticals or therapeutic groups jointly issued by four governmental parties.…”

Section: The Tools and Conditions For The Jobmentioning

confidence: 99%

Fighting Cancer around the World: A Framework for Action

et al. 2022

View full text Add to dashboard Cite

Tackling cancer is a major challenge right on the global level. Europe is only the tip of an iceberg of cancer around the world. Prosperous developed countries share the same problems besetting Europe–and the countries and regions with fewer resources and less propitious conditions are in many cases struggling often heroically against a growing tide of disease. This paper offers a view on these geographically wider, but essentially similar, challenges, and on the prospects for and barriers to better results in this ceaseless battle. A series of panels have been organized by the European Alliance for Personalised Medicine (EAPM) to identify different aspects of cancer care around the globe. There is significant diversity in key issues such as NGS, RWE, molecular diagnostics, and reimbursement in different regions. In all, it leads to disparities in access and diagnostics, patients’ engagement, and efforts for a better understanding of cancer.

show abstract

Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration

Cited by 7 publications

References 22 publications

Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review

Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Fighting Cancer around the World: A Framework for Action

Contact Info

Product

Resources

About